Aprea Therapeutics Reports $3.2 Million Net Loss in Q2 2025, Seeks Additional Funding

Aprea Therapeutics, Inc. reported a net loss of $3.2 million for the second quarter of 2025, a decrease from the $3.5 million loss recorded in the same period of 2024. The company’s grant revenue for the quarter was $118,111, significantly lower than the $561,574 reported a year earlier. For the first half of 2025, Aprea's net loss totaled $7.2 million, compared to $6.3 million for the same period in 2024. The decline in grant revenue is attributed to reduced funding from the National Institutes of Health, which impacted the company's overall financial performance.

Operating expenses for the second quarter of 2025 were $3.5 million, down from $4.4 million in the prior year, reflecting a decrease in both research and development costs and general and administrative expenses. Research and development expenses fell to $1.9 million from $2.6 million, primarily due to reduced costs associated with the initiation of the Phase 1 trial for APR-1051. General and administrative expenses also decreased to $1.6 million from $1.9 million, driven by lower professional fees and personnel costs.

In terms of strategic developments, Aprea continues to advance its clinical programs, particularly with its lead product candidates, APR-1051 and ATRN-119. The company is currently enrolling patients in clinical trials for both candidates, with data expected in the second half of 2025. Aprea's cash and cash equivalents stood at $16.5 million as of June 30, 2025, a decrease from $22.9 million at the end of 2024. The company has indicated that this cash balance may not be sufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern.

Aprea's employee headcount has seen a reduction, contributing to lower operational costs. The company is actively seeking additional funding to support its ongoing clinical trials and operational expenses. The outlook remains cautious, with management acknowledging the need for substantial additional financing to continue its development activities and maintain operations. The company is exploring various financing options, including public or private equity offerings, to secure the necessary capital for its future endeavors.